09/993,295
1/5/05 Wook

d his

(FILE 'HOME' ENTERED AT 09:24:47 ON 05 JAN 2005)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT 09:25:08 ON 05 JAN 2005

L1	1694	S (INTER ALPHA TRYPSIN INHIBITOR)
L2	1	S L1 AND (INSULIN RESISTANCE)
L3	6	S L1 AND DIABETE?
L4	21	S L1 AND INSULIN?
L5	5	S L3 AND L4
L6	2	DUPLICATE REMOVE L5 (3 DUPLICATES REMOVED)
L7	86	S L1 AND MARKER?
L8	24	S L7 AND DIAGNOS?
L9	20	DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)

=>

```
d his

     (FILE 'HOME' ENTERED AT 09:24:47 ON 05 JAN 2005)

     FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT
     09:25:08 ON 05 JAN 2005
L1         1694 S (INTER ALPHA TRYPSIN INHIBITOR)
L2            1 S L1 AND (INSULIN RESISTANCE)
L3            6 S L1 AND DIABETE?
L4           21 S L1 AND INSULIN?
L5            5 S L3 AND L4
L6            2 DUPLICATE REMOVE L5 (3 DUPLICATES REMOVED)
L7           86 S L1 AND MARKER?
L8           24 S L7 AND DIAGNOS?
L9           20 DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)

=>
```

ANSWER 13 OF 20 JAPIO (C) 2005 JPO on STN
AN 1997-159668 JAPIO
TI **DIAGNOSTIC** KIT FOR FIBRILLATION OF LIVER
IN UCHIDA KAZUO
PA IKAGAKU:KK
PI JP 09159668 A 19970620 Heisei
AI JP 1995-346521 (JP07346521 Heisei) 19951211
PRAI JP 1995-346521 19951211
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 1997
IC ICM G01N033-50
ICS G01N033-53
AB PROBLEM TO BE SOLVED: To **diagnose** fibrillation of liver and productivity of protein by measuring **inter-α trypsin inhibitor** in blood.
SOLUTION: **Inter-α trypsin inhibitor** in blood is selected as an object to be measured. The **inter-α trypsin inhibitor** is a protein produced only in liver cell and one of the extracellular matrix components of liver servable as a fibrillation **marker** of liver. Production of **inter-α trypsin inhibitor** in blood is reduced as the fibrillation of liver progresses and the concentration of **inter-α trypsin inhibitor** in blood can be discriminated clearly between a healthy person and a hepatocirrhosis patient. The **inter-α trypsin inhibitor** is invariant for various inflammatory diseases and reflects only the fibrillation of liver. Concentration **inter-α trypsin inhibitor** in blood can be measured conveniently by a routine method and the **inter-α trypsin inhibitor** also reflects productivity of protein of liver because it is produced only from the liver cell.

ANSWER 16 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1991:327839 BIOSIS
DN PREV199141024389; BR41:24389
TI ARE ALPHA-1 ANTICHYMOTRYPSIN AND **INTER-ALPHA TRYPSIN INHIBITOR** PERIPHERAL **MARKERS** OF ALZHEIMER'S DISEASE.
AU FURBY A [Reprint author]; LEYS D; DELACOURTE A; BUEE L; SOETAERT G; PETIT H
CS DEP NEUROL, INSERM U156, CHRU DE LILLE, HOPITAL B, 59037 LILLE, FR
SO Journal of Neurology Neurosurgery and Psychiatry, (1991) Vol. 54, No. 5, pp. 469.
CODEN: JNNPAU. ISSN: 0022-3050.
DT Article
FS BR
LA ENGLISH
ED Entered STN: 20 Jul 1991
Last Updated on STN: 20 Jul 1991
CC Behavioral biology - Human behavior 07004
Biochemistry methods - Proteins, peptides and amino acids 10054
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Diagnostic 12504
Metabolism - Proteins, peptides and amino acids 13012
Blood - Blood and lymph studies 15002
Blood - Other body fluids 15010
Nervous system - General and methods 20501
Nervous system - Pathology 20506
Psychiatry - Psychopathology, psychodynamics and therapy 21002
IT Major Concepts
Behavior; Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Metabolism; Neurology (Human Medicine, Medical Sciences); Pathology; Physiology; Psychiatry (Human Medicine, Medical Sciences)
IT Miscellaneous Descriptors
HUMAN SERUM CEREBROSPINAL FLUID DEMENTIA **DIAGNOSIS**
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
RN 39346-44-6 (**INTER-ALPHA-TRYPSIN INHIBITOR**)

ANSWER 7 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AN 2004:74536 BIOSIS

DN PREV200400077774

TI **Inter-alpha-trypsin inhibitor** as a **marker** for sepsis.

AU Lim, Yow-Pin [Inventor, Reprint Author]; Hixson, Douglas C. [Inventor]

CS ASSIGNEE: Rhode Island Hospital

PI US 6660482 December 09, 2003

SO Official Gazette of the United States Patent and Trademark Office Patents, (Dec 9 2003) Vol. 1277, No. 2. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).

DT Patent

LA English

ED Entered STN: 4 Feb 2004
Last Updated on STN: 4 Feb 2004

AB The invention provides a method of **diagnosing** sepsis in a mammal by contacting a bodily fluid from the mammal with a ligand which binds to an **inter-alpha trypsin inhibitor** (ITI) polypeptide under conditions sufficient to form an ITI-ligand complex and detecting the complex.

NCL 435071000

CC Biochemistry studies - General 10060
Pathology - Diagnostic 12504
Medical and clinical microbiology - General and methods 36001

IT Major Concepts
Biochemistry and Molecular Biophysics; Infection

IT Diseases
sepsis: bacterial disease, infectious disease, **diagnosis**
Sepsis (MeSH)

IT Chemicals & Biochemicals
inter-alpha trypsin inhibitor -ligand complex; **inter-alpha-trypsin inhibitor** polypeptide

ANSWER 3 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AN 2004:672718 CAPLUS

DN 141:222928

ED Entered STN: 18 Aug 2004

TI Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

AU Zhang, Zhen; Bast, Robert C., Jr.; Yu, Yinhua; Li, Jinong; Sokoll, Lori J.; Rai, Alex J.; Rosenzweig, Jason M.; Cameron, Bonnie; Wang, Young Y.; Meng, Xiao-Ying; Berchuck, Andrew; van Haaften-Day, Carolien; Hacker, Neville F.; de Bruijn, Henk W. A.; van der Zee, Ate G. J.; Jacobs, Ian J.; Fung, Eric T.; Chan, Daniel W.

CS Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA

SO Cancer Research (2004), 64(16), 5882-5890
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

CC 14-1 (Mammalian Pathological Biochemistry)

AB Early detection remains the most promising approach to improve long-term survival of patients with ovarian cancer. In a five-center case-control study, serum proteomic expressions were analyzed on 153 patients with invasive epithelial ovarian cancer, 42 with other ovarian cancers, 166 with benign pelvic masses, and 142 healthy women. Data from patients with early stage ovarian cancer and healthy women at two centers were analyzed independently and the results cross-validated to discover potential biomarkers. The results were validated using the samples from two of the remaining centers. After protein identification, biomarkers for which an immunoassay was available were tested on samples from the fifth center, which included 41 healthy women, 41 patients with ovarian cancer, and 20 each with breast, colon, and prostate cancers. Three biomarkers were identified as follows: (a) apolipoprotein A1 (down-regulated in cancer); (b) a truncated form of transthyretin (down-regulated); and (c) a cleavage fragment of **inter-.alpha.-trypsin inhibitor** heavy chain H4 (up-regulated). In independent validation to detect early stage invasive epithelial ovarian cancer from healthy controls, the sensitivity of a multivariate model combining the three biomarkers and CA125 [74% (95% CI, 52-90%)] was higher than that of CA125 alone [65% (95% CI, 43-84%)] at a matched specificity of 97% (95% CI, 89-100%). When compared at a fixed sensitivity of 83% (95% CI, 61-95%), the specificity of the model [94% (95% CI, 85-98%)] was significantly better than that of CA125 alone [52% (95% CI, 39-65%)]. These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer.

ST **inter alpha trypsin inhibitor** heavy chain biomarker ovarian cancer; transthyretin apolipoprotein A1 biomarker ovarian cancer **diagnosis**

IT Apolipoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(A-I; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(SHAP (serum-derived hyaluronan-associated protein); three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT **Diagnosis**
(cancer; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Ovary, neoplasm

(carcinoma; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Blood serum
Human
Tumor **markers**
(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Transthyretin
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Adam, B; Cancer Res 2002, V62, P3609 CAPLUS
(2) Bachorik, P; Clin Chem 1997, V43, P2364 CAPLUS
(3) Baggerly, K; Bioinformatics 2004, V20, P777 CAPLUS
(4) Banez, L; J Urol 2003, V170, P442 CAPLUS
(5) Bast, R; Int J Biol Markers 1998, V13, P179 CAPLUS
(6) Coussens, L; Nature (Lond) 2002, V420, P860 CAPLUS
(7) Cvetkovic, D; Clin Cancer Res 2003, V9, P1013 CAPLUS
(8) Diamandis, E; Clin Chem 2002, V48, P1198 CAPLUS
(9) Diamandis, E; J Natl Cancer Inst (Bethesda) 2004, V96, P353
(10) Diamandis, E; Lancet 2002, V360, P170 MEDLINE
(11) Diamandis, E; Mol Cell Proteomics 2004, V3, P367 CAPLUS
(12) Fung, E; Curr Opin Biotechnol 2001, V12, P65 CAPLUS
(13) Giordano, T; Am J Pathol 2001, V159, P1231 MEDLINE
(14) Hayashi, H; Gynecol Obstet Investig 1999, V47, P58 MEDLINE
(15) Hutchens, T; Rapid Commun Mass Spectrom 1993, V7, P576 CAPLUS
(16) Jacobs, I; Hum Reprod 1989, V4, P1 CAPLUS
(17) Jacobs, I; Lancet 1999, V353, P1207 MEDLINE
(18) Jemal, A; CA - Cancer J Clin 2002, V52, P23
(19) Jungner, I; Clin Chem 1998, V44, P1641 CAPLUS
(20) Kozak, K; Proc Natl Acad Sci USA 2003, V100, P12343 CAPLUS
(21) Kuesel, A; Int J Cancer 1992, V52, P341 CAPLUS
(22) Lawrie, L; Mol Pathol 2001, V54, P253 CAPLUS
(23) Li, J; Clin Chem 2002, V48, P1296 CAPLUS
(24) Mahlck, C; Gynecol Obstet Investig 1994, V37, P135 MEDLINE
(25) Matrisian, L; Cancer Res 2003, V63, P6105 CAPLUS
(26) Menon, U; Best Pract Res Clin Obstet Gynaecol 2002, V16, P469
(27) Metz, C; Semin Nucl Med 1978, V8, P283 MEDLINE
(28) Mok, S; J Natl Cancer Inst (Bethesda) 2001, V93, P1458 CAPLUS
(29) Nishimura, H; FEBS Lett 1995, V357, P207 CAPLUS
(30) Petricoin, E; J Natl Cancer Inst 2002, V94, P1576 CAPLUS
(31) Petricoin, E; Lancet 2002, V359, P572 CAPLUS
(32) Pu, X; Biochim Biophys Acta 1994, V1208, P338 CAPLUS
(33) Qu, Y; Clin Chem 2002, V48, P1835 CAPLUS
(34) Rai, A; Arch Pathol Lab Med 2002, V126, P1518 CAPLUS
(35) Roberts, D; DNA Cell Biol 2002, V21, P11 CAPLUS
(36) Rosenwald, A; N Engl J Med 2002, V346, P1937
(37) Skates, S; J Am Stat Assoc 2001, V96, P429
(38) van Bennekum, A; J Biol Chem 2001, V276, P1107 CAPLUS
(39) van Haaften-Day, C; Cancer (Phila) 2001, V92, P2837 CAPLUS
(40) van Nagell, J; Gynecol Oncol 2000, V77, P350
(41) van de Vijver, M; N Engl J Med 2002, V347, P1999 CAPLUS
(42) Vapnik, V; Statistical learning theory 1998, P736
(43) Vlahou, A; Am J Pathol 2001, V158, P1491 CAPLUS
(44) Woolas, R; Gynecol Oncol 1995, V59, P111 MEDLINE
(45) Yousef, G; Cancer Res 2003, V63, P2223 CAPLUS
(46) Yousef, G; Endocr Rev 2001, V22, P184 CAPLUS
(47) Yousef, G; Minerva Endocrinol 2002, V27, P157 MEDLINE
(48) Zhang, Z; Gynecol Oncol 1999, V73, P56 MEDLINE

(49) Zhang, Z; Methods of microarray data analysis: papers from CAMDA '00 2001, P125 CAPLUS
(50) Zhang, Z; Microarray data analysis II: papers from CAMDA '01 2002

ANSWER 3 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AN 2004:672718 CAPLUS

DN 141:222928

ED Entered STN: 18 Aug 2004

TI Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

AU Zhang, Zhen; Bast, Robert C., Jr.; Yu, Yinhua; Li, Jinong; Sokoll, Lori J.; Rai, Alex J.; Rosenzweig, Jason M.; Cameron, Bonnie; Wang, Young Y.; Meng, Xiao-Ying; Berchuck, Andrew; van Haaften-Day, Carolien; Hacker, Neville F.; de Bruijn, Henk W. A.; van der Zee, Ate G. J.; Jacobs, Ian J.; Fung, Eric T.; Chan, Daniel W.

CS Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA

SO Cancer Research (2004), 64(16), 5882-5890
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

CC 14-1 (Mammalian Pathological Biochemistry)

AB Early detection remains the most promising approach to improve long-term survival of patients with ovarian cancer. In a five-center case-control study, serum proteomic expressions were analyzed on 153 patients with invasive epithelial ovarian cancer, 42 with other ovarian cancers, 166 with benign pelvic masses, and 142 healthy women. Data from patients with early stage ovarian cancer and healthy women at two centers were analyzed independently and the results cross-validated to discover potential biomarkers. The results were validated using the samples from two of the remaining centers. After protein identification, biomarkers for which an immunoassay was available were tested on samples from the fifth center, which included 41 healthy women, 41 patients with ovarian cancer, and 20 each with breast, colon, and prostate cancers. Three biomarkers were identified as follows: (a) apolipoprotein A1 (down-regulated in cancer); (b) a truncated form of transthyretin (down-regulated); and (c) a cleavage fragment of **inter-.alpha.-trypsin inhibitor** heavy chain H4 (up-regulated). In independent validation to detect early stage invasive epithelial ovarian cancer from healthy controls, the sensitivity of a multivariate model combining the three biomarkers and CA125 [74% (95% CI, 52-90%)] was higher than that of CA125 alone [65% (95% CI, 43-84%)] at a matched specificity of 97% (95% CI, 89-100%). When compared at a fixed sensitivity of 83% (95% CI, 61-95%), the specificity of the model [94% (95% CI, 85-98%)] was significantly better than that of CA125 alone [52% (95% CI, 39-65%)]. These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer.

ST **inter alpha trypsin inhibitor** heavy chain biomarker ovarian cancer; transthyretin apolipoprotein A1 biomarker ovarian cancer **diagnosis**

IT Apolipoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(A-I; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(SHAP (serum-derived hyaluronan-associated protein); three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT **Diagnosis**
(cancer; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Ovary, neoplasm

(carcinoma; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Blood serum
Human
Tumor **markers**
(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Transthyretin
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Adam, B; Cancer Res 2002, V62, P3609 CAPLUS
(2) Bachorik, P; Clin Chem 1997, V43, P2364 CAPLUS
(3) Baggerly, K; Bioinformatics 2004, V20, P777 CAPLUS
(4) Banez, L; J Urol 2003, V170, P442 CAPLUS
(5) Bast, R; Int J Biol Markers 1998, V13, P179 CAPLUS
(6) Coussens, L; Nature (Lond) 2002, V420, P860 CAPLUS
(7) Cvetkovic, D; Clin Cancer Res 2003, V9, P1013 CAPLUS
(8) Diamandis, E; Clin Chem 2002, V48, P1198 CAPLUS
(9) Diamandis, E; J Natl Cancer Inst (Bethesda) 2004, V96, P353
(10) Diamandis, E; Lancet 2002, V360, P170 MEDLINE
(11) Diamandis, E; Mol Cell Proteomics 2004, V3, P367 CAPLUS
(12) Fung, E; Curr Opin Biotechnol 2001, V12, P65 CAPLUS
(13) Giordano, T; Am J Pathol 2001, V159, P1231 MEDLINE
(14) Hayashi, H; Gynecol Obstet Investig 1999, V47, P58 MEDLINE
(15) Hutchens, T; Rapid Commun Mass Spectrom 1993, V7, P576 CAPLUS
(16) Jacobs, I; Hum Reprod 1989, V4, P1 CAPLUS
(17) Jacobs, I; Lancet 1999, V353, P1207 MEDLINE
(18) Jemal, A; CA - Cancer J Clin 2002, V52, P23
(19) Jungner, I; Clin Chem 1998, V44, P1641 CAPLUS
(20) Kozak, K; Proc Natl Acad Sci USA 2003, V100, P12343 CAPLUS
(21) Kuesel, A; Int J Cancer 1992, V52, P341 CAPLUS
(22) Lawrie, L; Mol Pathol 2001, V54, P253 CAPLUS
(23) Li, J; Clin Chem 2002, V48, P1296 CAPLUS
(24) Mahlck, C; Gynecol Obstet Investig 1994, V37, P135 MEDLINE
(25) Matrisian, L; Cancer Res 2003, V63, P6105 CAPLUS
(26) Menon, U; Best Pract Res Clin Obstet Gynaecol 2002, V16, P469
(27) Metz, C; Semin Nucl Med 1978, V8, P283 MEDLINE
(28) Mok, S; J Natl Cancer Inst (Bethesda) 2001, V93, P1458 CAPLUS
(29) Nishimura, H; FEBS Lett 1995, V357, P207 CAPLUS
(30) Petricoin, E; J Natl Cancer Inst 2002, V94, P1576 CAPLUS
(31) Petricoin, E; Lancet 2002, V359, P572 CAPLUS
(32) Pu, X; Biochim Biophys Acta 1994, V1208, P338 CAPLUS
(33) Qu, Y; Clin Chem 2002, V48, P1835 CAPLUS
(34) Rai, A; Arch Pathol Lab Med 2002, V126, P1518 CAPLUS
(35) Roberts, D; DNA Cell Biol 2002, V21, P11 CAPLUS
(36) Rosenwald, A; N Engl J Med 2002, V346, P1937
(37) Skates, S; J Am Stat Assoc 2001, V96, P429
(38) van Bennekum, A; J Biol Chem 2001, V276, P1107 CAPLUS
(39) van Haaften-Day, C; Cancer (Phila) 2001, V92, P2837 CAPLUS
(40) van Nagell, J; Gynecol Oncol 2000, V77, P350
(41) van de Vijver, M; N Engl J Med 2002, V347, P1999 CAPLUS
(42) Vapnik, V; Statistical learning theory 1998, P736
(43) Vlahou, A; Am J Pathol 2001, V158, P1491 CAPLUS
(44) Woolas, R; Gynecol Oncol 1995, V59, P111 MEDLINE
(45) Yousef, G; Cancer Res 2003, V63, P2223 CAPLUS
(46) Yousef, G; Endocr Rev 2001, V22, P184 CAPLUS
(47) Yousef, G; Minerva Endocrinol 2002, V27, P157 MEDLINE
(48) Zhang, Z; Gynecol Oncol 1999, V73, P56 MEDLINE

(49) Zhang, Z; Methods of microarray data analysis: papers from CAMDA '00 2001, P125 CAPLUS
(50) Zhang, Z; Microarray data analysis II: papers from CAMDA '01 2002

ANSWER 16 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AN 1991:327839 BIOSIS

DN PREV199141024389; BR41:24389

TI ARE ALPHA-1 ANTICHYMOTRYPSIN AND **INTER-ALPHA TRYPSIN INHIBITOR** PERIPHERAL **MARKERS** OF ALZHEIMER'S DISEASE.

AU FURBY A [Reprint author]; LEYS D; DELACOURTE A; BUEE L; SOETAERT G; PETIT H

CS DEP NEUROL, INSERM U156, CHRU DE LILLE, HOPITAL B, 59037 LILLE, FR

SO Journal of Neurology Neurosurgery and Psychiatry, (1991) Vol. 54, No. 5, pp. 469.
CODEN: JNNPAU. ISSN: 0022-3050.

DT Article

FS BR

LA ENGLISH

ED Entered STN: 20 Jul 1991
Last Updated on STN: 20 Jul 1991

CC Behavioral biology - Human behavior 07004
Biochemistry methods - Proteins, peptides and amino acids 10054
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Diagnostic 12504
Metabolism - Proteins, peptides and amino acids 13012
Blood - Blood and lymph studies 15002
Blood - Other body fluids 15010
Nervous system - General and methods 20501
Nervous system - Pathology 20506
Psychiatry - Psychopathology, psychodynamics and therapy 21002

IT Major Concepts
Behavior; Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Metabolism; Neurology (Human Medicine, Medical Sciences); Pathology; Physiology; Psychiatry (Human Medicine, Medical Sciences)

IT Miscellaneous Descriptors
HUMAN SERUM CEREBROSPINAL FLUID DEMENTIA **DIAGNOSIS**

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 39346-44-6 (**INTER-ALPHA-TRYPSIN INHIBITOR**)

Unable to print
Check 1/5/05